Suggestions
Lev Osherovich
Scientist, Company Builder, Investor
Lev Osherovich is a multifaceted professional with a strong background in science, venture capitalism, and biotechnology. He is currently the Founding Director at StealthCo and resides in Basel, Switzerland.2
Academic Background
Osherovich holds a Ph.D. in Biochemistry from the University of California, San Francisco, and a B.S. in Molecular and Cell Biology with a focus on Genetics from the University of California, Berkeley.
Professional Experience
Throughout his career, Lev Osherovich has held various significant positions:
- Founding Director at StealthCo (current role)2
- Partner at Delin Ventures
- Director of Innovation and Sourcing at Versant Ventures
- Academic Liaison at Versant Ventures
- Business Development Associate at Inception Sciences
- Senior Writer at BioCentury Publications
- Consulting Scientific Editor at Zenis Co., Ltd.
He has also served as a Postdoctoral Fellow at the University of California, San Francisco, and a Research Fellow at the University of Kent.
Expertise and Focus
Osherovich specializes in:
- Identifying and evaluating early-stage drug discovery projects
- Bridging the gap between academic research and industry
- Discovering novel therapeutic opportunities
His LinkedIn profile describes him as a "Scientist, Company Builder, Investor" who leverages academic and industry knowledge to uncover unexpected therapeutic opportunities and launch new drug discovery ventures.2
Innovations and Contributions
Lev Osherovich has been involved in patent applications for various inventions, demonstrating his active role in scientific innovation and drug discovery.1
Recent Activities
Osherovich maintains an active presence on LinkedIn, sharing insights and commenting on developments in the biotech industry. Recent posts include discussions on:
- Simulations for experiments in drug discovery3
- Advancements in RNA-based therapies4
- Developments in cell therapy manufacturing5
Lev Osherovich's diverse experience and expertise make him a notable figure in the intersection of scientific research, biotechnology, and venture capitalism.
Highlights
https://lnkd.in/dKKQbAN8
Unlike DNA, RNA plays numerous active roles in living cells. It acts as an enzyme, splicing and dicing other RNA molecules or assembling proteins — the stuff of which all life is built — from amino acid building blocks. It keeps stem cells active and forestalls aging by building out the DNA at the ends of our chromosomes.
RNA discoveries have led to new therapies, such as the use of antisense RNA to help treat children afflicted with the devastating disease spinal muscular atrophy. The mRNA vaccines, which saved millions of lives during the Covid pandemic, are being reformulated to attack other diseases, including some cancers. RNA research may also be helping us rewrite the future; the genetic scissors that give CRISPR its breathtaking power to edit genes are guided to their sites of action by RNAs.
Although most scientists now agree on RNA's bright promise, we are still only beginning to unlock its potential. Consider, for instance, that some 75 percent of the human genome consists of dark matter that is copied into RNAs of unknown function. While some researchers have dismissed this dark matter as junk or noise, I expect it will be the source of even more exciting breakthroughs.
We don’t know yet how many of these possibilities will prove true. But if the past 40 years of research have taught me anything, it is never to underestimate this little molecule.
Congratulations to Szabolcs Nagy, Daniel Veres MD PhD and the Turbine team on getting to the next level with this series A financing. Special thanks to Delin Ventures BoD member Natalia Novac for doing the hard work to make this dream a reality.
